When to Consider Switching GLP-1 Medications Weight loss plateaus often occur 612 months into semaglutide therapy, when the body's adaptation reduces the medication's initial potency
The decrease in this biomarker was more substantial with IGF-1 LR3, potentially up to threefold compared to IGF-1
PlexusDx's Precision Peptide Genetic Test reveals predispositions in GLP1R, GIPR, FTO, and MC4R pathways, which may provide context for medication response potential
This means the body burns fewer calories at rest
The decision to escalate to maximum dose should be made carefully between you and your provider, weighing results achieved at lower doses against the increased side effect burden
If you already have a knowledgeable prescriber who is willing to manage your tirzepatide treatment actively, going direct to a compounding pharmacy might save money